What is CVS stock price target for 2026?

WallStSmart's 12-month price target for CVS Health Corp is $42.02, representing 49.9% downside from the current price of $83.90.

What is CVS stock forecast?

CVS Health Corp forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is CVS undervalued based on price targets?

Our DCF intrinsic value for CVS Health Corp is $340.87, against a current price of $83.90. The margin of safety is 77.40%.

CVS

CVS Health Corp

NYSE: CVS · HEALTHCARE · HEALTHCARE PLANS

$83.90

+3.61% today

Updated 2026-04-29

Market cap

$99.89B

P/E ratio

56.07

P/S ratio

0.25x

EPS (TTM)

$1.39

Dividend yield

3.37%

52W range

$56 – $84

Volume

7.7M

Market cap

$99.89B

P/E ratio

56.07

P/S ratio

0.25x

EPS (TTM)

$1.39

Dividend yield

3.37%

52W range

$56 – $84

Volume

7.7M

CVS Health Corp (CVS) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$83.90

Consensus

$94.61

+12.77%

2030 Target

$4,681.31

+5479.63%

DCF

$340.87

+77.40% MoS

Current price

$83.90

Analyst consensus

$94.61

+12.77%

2030 Target

$4,681.31

+5479.63%

Intrinsic (DCF)

$340.87

+77.40% MoS

18 analysts:

11 Buy4 Hold0 Sell

Management guidance

No specific CEO revenue targets found in available data. Latest company results show FY2025 revenue of $402.07B with 7.85% growth. Management is executing strategic initiatives including 60 new store openings in 2026, expansion of pharmacy-only format, digital health platform launch (Health100 with Google Cloud), and MinuteClinic integration, but no explicit forward revenue guidance through 2030 was disclosed.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$7,804.64

$489.8B Rev × 20x P/S

Base case (2030)

$4,681.31

$489.8B Rev × 12x P/S

Bear case (2030)

$3,123.33

$489.8B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$357.8B	$372.8B	$402.1B	$409.6B	$427.9B	$447.5B	$468.2B	$489.8B
Revenue growth	—	4.2%	7.8%	1.9%	4.5%	4.6%	4.6%	4.6%
EPS	$8.74	$5.42	$6.75	$7.25	$8.27	$9.10	$9.95	$10.85
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$3,917.02	$4,093.39	$4,277.12	$4,475.54	$4,681.31

Catalysts & risks

Growth catalysts

+ Pharmacy-only store expansion (19+ locations planned for 2026) targeting underserved markets

+ Digital health platform (Health100 AI with Google Cloud) driving consumer engagement and data monetization

+ PBM reform regulatory clarity reducing structural headwinds post-FTC settlements

+ Aetna Medicare Advantage stabilization and integrated care model expansion

+ MinuteClinic scale driving higher-margin primary care revenue

Key risks

- Class action lawsuit alleging PBM kickback schemes and formulary access manipulation

- Regulatory scrutiny on Medicare Advantage overbilling (Aetna settlements totaling $118M+ in 2026)

- PBM industry headwinds from transparency rules and rebate reform reducing profitability

- Retail pharmacy margin compression from wage inflation and theft/shrinkage

- Competition from Amazon Pharmacy and integrated health platforms

Methodology

CVS Health Corp's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 18 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.